A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome
Trial details
- Registry ID
- NCT03162783
- Phase
- Phase 2
The FDA issued a complete response letter for ADX-102 Ophthalmic Solution (0.5%) / Reproxalap on 16 Mar 2026.
Drug identity checked against registry records
Also recorded as Reproxalap
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye SyndromeNCT03162783 | ALDX | Phase 2 | Completed | 2017-07-06Actual |
| SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.NCT03131154 | ALDX | Phase 3 | Completed | 2019-04-19Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2026-03-16Day | ADX-102 Ophthalmic Solution (0.5%)Aldeyra Therapeutics, Inc. · ALDX | FDA complete response letterComplete response letter | Not specified | Open original sourceRead source excerpt{"application_number": ["NDA 216442"], "letter_date": "03/16/2026", "letter_type": "COMPLETE RESPONSE", "company_name": "Aldeyra Therapeutics, Inc.", "file_name": "CRL_NDA216442_20260316.pdf"} First seen: 26 Sep 2026 · Evidence last checked: 26 Sep 2026 |